Elliot James Glotfelty

2017- Drug Design and Development/ Neuroscience National Institute on Aging/Karolinska Institutet, Solna, Stockholms län, Sweden 
neurodegeneration, SNARE proteins, botunlinum toxin
"Elliot Glotfelty"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

McNutt PM, Vazquez-Cintron EJ, Tenezaca L, et al. (2021) Neuronal delivery of antibodies has therapeutic effects in animal models of botulism. Science Translational Medicine. 13
Yu SJ, Chen S, Yang YY, et al. (2020) PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease. Frontiers in Neuroscience. 14: 785
Glotfelty EJ, Olson L, Karlsson TE, et al. (2020) Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease. Expert Opinion On Investigational Drugs. 1-8
Greig NH, Lecca D, Hsueh SC, et al. (2019) (-)-Phenserine tartrate (PhenT) as a treatment for traumatic brain injury. Cns Neuroscience & Therapeutics
Li Y, Glotfelty EJ, Namdar I, et al. (2019) Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury. Experimental Neurology. 113113
Glotfelty EJ, Delgado T, Tovar-Y-Romo LB, et al. (2019) Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. Acs Pharmacology & Translational Science. 2: 66-91
Bader M, Li Y, Lecca D, et al. (2018) Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury. Neurobiology of Disease
Chen S, Yu SJ, Li Y, et al. (2018) Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease. Scientific Reports. 8: 10722
Vazquez-Cintron EJ, Beske PH, Tenezaca L, et al. (2017) Engineering Botulinum Neurotoxin C1 as a Molecular Vehicle for Intra-Neuronal Drug Delivery. Scientific Reports. 7: 42923
McNutt PM, Tuznik KM, Glotfelty EJ, et al. (2016) Contributions of tissue-specific pathologies to corneal injuries following exposure to SM vapor. Annals of the New York Academy of Sciences
See more...